NCT02058641View on ClinicalTrials.gov

Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)

PHASE1CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

February 26, 2014

Primary Completion Date

August 18, 2014

Study Completion Date

August 18, 2014

Conditions

Atherosclerosis

Interventions

DRUG

Darapladib

EC tablet with a unit dose strength of 160 mg administered once daily orally for 11 days.

Trial Locations (1)

CB2 0GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY